ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

New Oral Anticoagulants in the Treatment of Patients with Atrial Fibrillation

Journal: Galician Medical Journal (Vol.21, No. 2)

Publication Date:

Authors : ; ;

Page : 23-26

Keywords : atrial fibrillation; systemic embolism; stroke; new oral anticoagulants;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

New oral anticoagulants are important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients. Recently for prevention and treatment of thromboembolism in atrial fibrillation patients antagonists vitamin K, in particular warfarin were used. However, narrow therapeutic window, the need for lifelong monitoring of coagulation and negative interactions with many food products and pharmaceuticals reduces its use. Besides, long-term use of warfarin and its antagonism against vitamin K, which is the regulator of elimination of calcium from the body, can cause calcification of the coronary arteries and valvular heart. In connection with this new oral anticoagulants: dabigatran, rivaroxaban, apixaban are actively used in modern conditions. Their efficacy and safety is proved in randomized clinical trials: RF-LY, ROCKET -AF, ARISTOTLE.

Last modified: 2015-11-25 17:35:05